胰高血糖素样肽1受体激动剂与静脉血栓栓塞风险:随机对照试验的系统综述与Meta分析
系统综述与Meta分析纳入27项安慰剂对照随机对照试验共84003例2型糖尿病或肥胖患者,比较胰高血糖素样肽1受体激动剂(GLP-1RA)与安慰剂对静脉血栓栓塞(VTE)风险的影响。GLP-1RA组VTE中位发生率为每1000患者年1.1例,安慰剂组为2.5例;总体VTE风险无统计学显著差异(RR 0.70,95%CI 0.46-1.07),但肺栓塞风险显著降低(RR 0.60,95%CI 0.39-0.94)。
要点
- GLP-1RA与安慰剂相比总体VTE风险无统计学显著差异(RR 0.70,95%CI 0.46-1.07)。
- GLP-1RA与肺栓塞风险显著降低相关(RR 0.60,95%CI 0.39-0.94)。
- 深静脉血栓(RR 1.21,95%CI 0.69-2.12)与其他部位VTE(RR 0.56,95%CI 0.25-1.26)风险无显著差异。
核心结论
- 在2型糖尿病或肥胖患者的随机试验Meta分析中,GLP-1RA与总体VTE风险显著降低无关,但与肺栓塞风险降低相关。
研究设计与样本
- 系统综述与Meta分析,纳入27项安慰剂对照随机对照试验,共84003例2型糖尿病或肥胖患者。
- 检索5个数据库,检索时间从建库至2024年10月。
- 主要结局为VTE(肺栓塞、深静脉血栓及其他部位VTE的复合终点),次要结局为各单项事件。
主要发现
- GLP-1RA组VTE中位发生率为每1000患者年1.1例,安慰剂组为每1000患者年2.5例。
- GLP-1RA组与安慰剂组总体VTE风险无统计学显著差异(RR 0.70,95%CI 0.46-1.07)。
- GLP-1RA与肺栓塞风险显著降低相关(RR 0.60,95%CI 0.39-0.94)。
- 深静脉血栓风险无显著差异(RR 1.21,95%CI 0.69-2.12)。
- 其他部位VTE风险无显著差异(RR 0.56,95%CI 0.25-1.26)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is an established risk factor for venous thromboembolism (VTE). Observational data suggest that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce the risk of VTE. However, the effects of GLP-1RAs on VTE have not been tested in randomized controlled trials (RCTs). OBJECTIVES: To investigate the impact of GLP-1RAs on VTE risk using data from RCTs. METHODS: We conducted a systematic review and meta-analysis of placebo-controlled RCTs focusing on GLP-1RA use in patients with type 2 diabetes mellitus (T2DM) or obesity. Five databases were searched from inception to October 2024. The primary outcome was VTE, which was a composite of pulmonary embolism (PE), deep vein thrombosis, and VTE at other sites, and the secondary outcomes were the individual events. RESULTS: Twenty-seven RCTs with 84 003 patients were analyzed. The median incidence of VTE was 1.1 and 2.5 per 1000 patient-years in the GLP-1RA and placebo groups, respectively. There was no statistically significant difference in overall VTE risk between GLP-1RA and placebo groups (risk ratio [RR], 0.70; 95% CI, 0.46-1.07). However, GLP-1RAs were associated with a significantly lower risk of PE (RR, 0.60; 95% CI, 0.39-0.94). In contrast, there were no significant differences in the risk of deep vein thrombosis (RR, 1.21; 95% CI, 0.69-2.12) or VTE at other sites (RR, 0.56; 95% CI, 0.25-1.26). CONCLUSION: In this meta-analysis of randomized trials, GLP-1RAs were not associated with a significant reduction in overall VTE risk but were associated with a lower risk of PE among patients with T2DM or obesity.
引用
- Chiang CH, Chang YC, Yu CC, et al. Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2025. PMID: 40602613. doi:10.1016/j.jtha.2025.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。